Inclusion Criteria:

The diagnosis of HCC is made either by histological examination of tumor tissue or imaging
evidence of a typical space-occupying lesion in the liver together with a serum AFP
concentration of above 500 ng/ml (normal value, 10 ng/ml) in a known carrier of hepatitis
B or C, or AFP above 400 ng/ml in non Hepatitis B or C carrier.

- Patients with unresectable HCC that is not amenable to liver transplantation nor
local ablative technique and who are not suitable for any conventional systemic
therapy (including sorafenib and chemotherapy).

- Patients with Child-Pugh Class C liver cirrhosis (Child-Pugh Scores of 10-15 points).
Patients with Child-Pugh Class A or B liver cirrhosis who are not eligible for
conventional therapy or other clinical trials or who refuse conventional therapy are
included

- Life Expectancy of at least 12 weeks

- All patients should have anti-HBc antibodies tested if HBs Ag is negative. If
anti-HBc is positive, HBV DNA detection should be performed to determine viral load.
An undetectable Hep B DNA level (DNA levels < 12 IU/ml) in the presence of a positive
Hep B core total antibody would indicate no active hepatitis infection and the
subject would still be eligible for this trial.

- Age >21 years.

- Performance status ECOG 0 - 2

- Patients must have normal organ and marrow function as defined below:

Absolute neutrophil count > 1.5 x 109/L Platelets > 50 x 109/L Haemoglobin > 9.0g/dl Total
bilirubin < 51umol/L (3 mg /dL) AST (SGOT)/ALT (SGPT) < 5 X institutional ULN Creatinine <
1.5 ULN INR <1.7 or prothrombin time (PT) <4 seconds above ULN

- Patients who have not received any local or systemic treatment in the last 4 weeks.

- Measurable disease according to RECIST

- Ability to understand and the willingness to sign a written informed consent
document.

- Ability to swallow oral medication

- The effects of C versicolor on the developing human fetus are unknown. For this
reason, woman of child-bearing potential and men must agree to use adequate
contraception (hormonal or barrier method of birth control; abstinence) prior to
study entry and for the duration of study participation. Should a woman become
pregnant or suspect she is pregnant while participating in this study, she should
inform her treating physician immediately.

Exclusion Criteria:

- Patients with a history of prior malignancy that is distinct in site and histology
from HCC except non-melanoma skin cancer. Any cancer curatively treated more than 3
years prior to entry is permitted.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, intractable ascites that could not be controlled by medical therapy

- Prior use of C versicolor or Yunzhi for HCC

- Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering
the study or those who have not recovered from adverse events due to agents
administered more than 4 weeks earlier

- Patients who are using other chinese herbal therapies concurrently or on any other
investigation agents for treatment of their cancer

- Known of history of allergic reactions attributed to compounds of similar chemical or
biologic composition used in the study.

- Presence of active hepatitis B/C flare.

- Known history of Human Immunodeficiency Virus (HIV) Infection

- Gastrointestinal disease which could affect the absorption or pharmacokinetics of the
study drug as determined by investigator

- Psychiatric illness/social situations that would limit compliance with study
requirements. Patients with severe depression or psychiatric disorders will be
excluded.

- Known alcohol and/or substance abuser that may interfere with the subject's
participation in the study or evaluation of study results.

- Pregnancy or breast-feeding subjects. All female patients with reproductive potential
must have a negative pregnancy test (serum or urine) within the 14 days prior to
study enrollment and must be willing to use adequate contraception

- Patients suffering from autoimmune disease, patients on concomitant long-term
immunosuppressant therapy and those scheduled to receive bone marrow transplants